These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34449050)

  • 1. Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation close up.
    Kurosawa S; Yamaguchi T; Mori A; Matsuura T; Mori T; Tanaka M; Kondo T; Umemoto Y; Goto H; Yoshioka S; Machida S; Sato T; Katayama Y; Kato S; Shono K; Mizuno I; Fujiwara SI; Kohno A; Takahashi M; Fukuda T
    J Cancer Surviv; 2022 Oct; 16(5):1004-1015. PubMed ID: 34449050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation.
    Kurosawa S; Yamaguchi T; Mori A; Matsuura T; Masuko M; Murata M; Tashiro H; Kako S; Satake A; Hagihara M; Ota S; Saito T; Kagawa K; Matsuo Y; Itonaga H; Uoshima N; Yamaguchi H; Naito K; Takahashi M; Fukuda T
    J Cancer Surviv; 2023 Jun; 17(3):781-794. PubMed ID: 36048313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Job resignation after cancer diagnosis among working survivors in Japan: timing, reasons and change of information needs over time.
    Takahashi M; Tsuchiya M; Horio Y; Funazaki H; Aogi K; Miyauchi K; Arai Y
    Jpn J Clin Oncol; 2018 Jan; 48(1):43-51. PubMed ID: 29036512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.
    Bhatt NS; Brazauskas R; Salit RB; Syrjala K; Bo-Subait S; Tecca H; Badawy SM; Baker KS; Beitinjaneh A; Bejanyan N; Byrne M; Dias A; Farhadfar N; Freytes CO; Ganguly S; Hashmi S; Hayashi RJ; Hong S; Inamoto Y; Jamani K; Kasow KA; Khera N; Krem MM; Lazarus HM; Lee CJ; Lee S; Majhail NS; Malone AK; Marks DI; Mau LW; Mayo SJ; Muffly LS; Nathan S; Nishihori T; Page KM; Preussler J; Rangarajan HG; Rotz SJ; Salooja N; Savani BN; Schears R; Schechter-Finkelstein T; Schiller G; Shah AJ; Sharma A; Wang T; Wirk B; Battiwalla M; Schoemans H; Hamilton B; Buchbinder D; Phelan R; Shaw B
    Transplant Cell Ther; 2021 Aug; 27(8):679.e1-679.e8. PubMed ID: 33895402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation.
    Bhatt NS
    Curr Hematol Malig Rep; 2022 Dec; 17(6):228-242. PubMed ID: 36194316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Return-to-Work Guidelines and Programs for Post-Hematopoietic Cell Transplantation Survivors: An Initial Survey.
    Salit RB; Lee SJ; Burns LJ; Shaw BE; Majhail NS; Bhatt NS; Wood WA; Syrjala KL
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1520-1526. PubMed ID: 32360563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Status and Needs of Long-Term Follow-Up Clinics for Hematopoietic Cell Transplantation Survivors: Results of a Nationwide Survey in Japan.
    Kurosawa S; Mori A; Tsukagoshi M; Onishi Y; Ohwada C; Mori T; Goto H; Asano-Mori Y; Nawa Y; Hino M; Fukuchi T; Mori Y; Yamahana R; Inamoto Y; Fukuda T
    Biol Blood Marrow Transplant; 2020 May; 26(5):949-955. PubMed ID: 31962164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
    Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective predictors of return to work in the 5 years after hematopoietic cell transplantation.
    Kirchhoff AC; Leisenring W; Syrjala KL
    J Cancer Surviv; 2010 Mar; 4(1):33-44. PubMed ID: 19936935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term implications of cancer for work and financial wellbeing: Evidence from autologous hematopoietic cell transplantation (HCT) survivors.
    Stepanikova I; Powroznik K; Cook KS; Tierney DK; Laport G
    Maturitas; 2017 Nov; 105():119-125. PubMed ID: 28780252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of post-cancer diagnosis resignation among Japanese cancer survivors.
    Endo M; Muto G; Imai Y; Mitsui K; Nishimura K; Hayashi K
    J Cancer Surviv; 2020 Apr; 14(2):106-113. PubMed ID: 31721037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Pretransplantation Quality of Life and Its Post-Transplantation Longitudinal Change after Allogeneic Hematopoietic Cell Transplantation: A Prospective Study That Administered the Short-Form Health Survey (SF-12) and EuroQol 5.
    Kurosawa S; Yamaguchi T; Mori A; Tsukagoshi M; Okuda I; Ikeda M; Fuji S; Yamashita T; Ogawa C; Ito A; Tanaka T; Inamoto Y; Kim SW; Fukuda T
    Transplant Cell Ther; 2021 Nov; 27(11):935.e1-935.e9. PubMed ID: 34371214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplantation employment status of adult survivors of childhood allogeneic hematopoietic cell transplant: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR).
    Bhatt NS; Brazauskas R; Tecca HR; Carreras J; Burns LJ; Phelan R; Salit RB; Syrjala KL; Talano JM; Shaw BE
    Cancer; 2019 Jan; 125(1):144-152. PubMed ID: 30368771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The provision of workplace accommodations following cancer: survivor, provider, and employer perspectives.
    Stergiou-Kita M; Pritlove C; van Eerd D; Holness LD; Kirsh B; Duncan A; Jones J
    J Cancer Surviv; 2016 Jun; 10(3):489-504. PubMed ID: 26521166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study.
    Soejima T; Shiohara M; Ishida Y; Inoue M; Hayakawa A; Sato A; Kamibeppu K; Atsuta Y; Yamashita T
    Int J Hematol; 2021 Apr; 113(4):566-575. PubMed ID: 33386599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation.
    Rotz SJ; Yi JC; Hamilton BK; Wei W; Preussler JM; Cerny J; Deol A; Jim H; Khera N; Hahn T; Hashmi SK; Holtan S; Jaglowski SM; Loren AW; McGuirk J; Reynolds J; Saber W; Savani BN; Stiff P; Uberti J; Wingard JR; Wood WA; Baker KS; Majhail NS; Syrjala KL
    Transplant Cell Ther; 2022 Oct; 28(10):701.e1-701.e7. PubMed ID: 35872304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
    Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
    Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation.
    Epperla N; Hamadani M; Ahn KW; He F; Kodali D; Kleman A; Hari PN; Pasquini M; Fenske TS; Craig MD; Kanate AS; Bachanova V
    Biol Blood Marrow Transplant; 2018 May; 24(5):983-988. PubMed ID: 29410340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
    Fenske TS; Zhang MJ; Carreras J; Ayala E; Burns LJ; Cashen A; Costa LJ; Freytes CO; Gale RP; Hamadani M; Holmberg LA; Inwards DJ; Lazarus HM; Maziarz RT; Munker R; Perales MA; Rizzieri DA; Schouten HC; Smith SM; Waller EK; Wirk BM; Laport GG; Maloney DG; Montoto S; Hari PN
    J Clin Oncol; 2014 Feb; 32(4):273-81. PubMed ID: 24344210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.